Division: Pharmacy Policy	Subject: State of Florida's Agency for Health Care Administration's Prior Authorization Criteria
Original Development Date: Original Effective Date: Revision Date:	March 25, 2020

SUNOSI™ (solriamfetol)

LENGTH OF AUTHORIZATION: ONE YEAR

REVIEW CRITERIA:

Narcolepsy

- The patient must be 18 years of age or older;
- The patient has a diagnosis of narcolepsy according to International Classification of Sleep Disorders (ICSD-3) or Diagnostic and Statistical Manual of Mental Disorders (DSM-5) criteria; **OR**
- The patient has excessive daytime sleepiness associated with narcolepsy as confirmed by documented sleep testing (e.g. polysomnography, multiple sleep latency test);
- Trial and failure of modafinil.

Obstructive Sleep Apnea (OSA)

- The patient must be 18 years of age or older **AND**
- The patient must have a diagnosis of OSA according to ICSD-3 criteria **OR**
- The patient has excessive daytime sleepiness associated with OSA as confirmed by documented sleep testing (e.g. polysomnography, multiple sleep latency test) **AND**
- Compliant use of continuous positive airway pressure (CPAP) at least a month prior to trial of Sunosi™; **AND**
- Trial and failure to modafinil; **AND**
- Modalities to treat the underlying airway obstruction should be continued during treatment with Sunosi™.

DOSING AND ADMINISTRATION:

Narcolepsy:
Recommended starting dose is 75mg once daily upon awakening. Avoid administration within 9 hours of planned bedtime because of the potential to interfere with sleep. The maximum dose is 150mg once daily.

Obstructive Sleep Apnea:
Recommending starting dose is 37.5mg once daily upon awakening. Avoid administration 9 hours of planned bedtime because of the potential to interfere with sleep. The maximum dose is 150mg once daily

Dosage Forms: 75mg (functionally scored) and 150mg